论文部分内容阅读
目的:评价拉莫三嗪对癫癎患者生活质量的影响。方法:采用多中心、前瞻性的研究方法,对新诊断癫癎患者应用拉莫三嗪治疗,并在基线期及用药6个月后,采用QOLIE-31、MOS SF-36量表、数字符号转换测验、HAMD抑郁量表和女性专用调查问卷对患者进行生活质量评价。结果:共纳入新诊断癫癎患者282例。MOS SF-36量表的8个项目得分在用药后均有显著提高(P<0.01);QOLIE-31问卷中“对癫癎的担心”、“情绪”、“活力”、“认知”、“药物不良反应”、“社会功能”及“总体自身健康评价”项目得分在用药后均有显著提高(P<0.01)。用药后,患者Hamilton抑郁量表平均3.65分,显著低于基线期6.42分(P<0.01);数字符号转换测验得分在用药后与基线期比较有显著提高(P<0.01)。结论:拉莫三嗪初始单药治疗能在一定程度上改善新诊断癫癎患者的生活质量。
Objective: To evaluate the impact of lamotrigine on quality of life in patients with epilepsy. Methods: A multi-center prospective study was conducted to evaluate the efficacy of lamotrigine in newly diagnosed epilepsy patients. At baseline and 6 months after treatment, the QOLIE-31, MOS SF-36, Conversion test, HAMD depression scale and female special questionnaire to evaluate the quality of life of patients. Results: A total of 282 newly diagnosed epilepsy patients were enrolled. The scores of 8 items of MOS SF-36 scale were significantly increased after treatment (P <0.01). In the QOLIE-31 questionnaire, “the worry about epilepsy”, “emotion”, “vitality” , “Cognitive”, “Adverse Drug Reaction”, “Social Function” and “Overall Self Health Evaluation” all increased significantly after treatment (P <0.01). After treatment, the Hamilton depression scale was 3.65 on average, significantly lower than the baseline (6.42) (P <0.01). The score of digital sign conversion test was significantly increased (P <0.01) after treatment compared with baseline. Conclusion: The initial monotherapy with lamotrigine can improve the quality of life of newly diagnosed epileptic patients to a certain extent.